Rick Simpson Oil (RSO) in Alaska: The Complete Guide

From the remote communities of the Bush to the streets of Anchorage, from the fishing docks of Kodiak to the military bases of Fairbanks — we know that Alaskans face unique challenges when it comes to healthcare access, pain management, and quality of life. The Last Frontier demands resilience. But sometimes, resilience needs support.

We’re OilWell Cannabis, and this guide exists because too many Alaskans have asked the same questions: What is RSO? Does it actually work? Is it legal to ship here? How do I know what I’m getting?

This is the most comprehensive education on Rick Simpson Oil ever written for Alaska residents. We’ve included every scientific citation, every cannabinoid profile, every terpene detail, and every honest assessment of what the evidence actually shows — not just what marketing claims want you to believe.

Whether you’re battling cancer in Juneau, managing chronic pain in Bethel, dealing with PTSD as a veteran in Wasilla, or simply curious about cannabinoid medicine in Eagle River — this guide is for you.

What Is Rick Simpson Oil (RSO)?

Rick Simpson Oil is a concentrated cannabis extract that has become one of the most searched terms in cannabinoid medicine. But the story behind RSO — and the truth about what it actually is — is far more nuanced than most people realize.

Who Is Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor. He was not a scientist. He was a power engineer — a blue-collar tradesman whose path into cannabis advocacy began because the medical system failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding. He suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine could not resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. When he asked his physician to support cannabis as an alternative, the request was refused.

Simpson learned about a 1974 study at the Medical College of Virginia where THC was reported to slow or shrink tumors in mice. That study — originally designed to demonstrate harm — became a reference point in his advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions. According to his account, the bumps disappeared within days. No independent medical verification exists. No biopsy confirmation was published. But this personal experience became the origin story of RSO.

Important context: Simpson’s account is presented as his personal testimony. The absence of clinical documentation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The Crusade That Followed

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. He gave it away for free. He charged nothing. By his own account, he helped dozens of people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and other conditions.

His story reached a global audience through the 2005 documentary Run From The Cure. The film was distributed freely online and became foundational in cannabis communities worldwide. Many Alaskans first learned about RSO through this documentary or through the online networks that shared it.

Simpson’s advocacy brought him into direct conflict with Canadian law. The RCMP raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, he eventually left Canada for Europe.

In 2012, he published Phoenix Tears: The Rick Simpson Story, and maintained phoenixtears.ca as his primary platform for information.

Throughout his public career, Simpson maintained that cannabis oil could cure cancer and other diseases, and that pharmaceutical companies and government agencies were actively suppressing this knowledge. His conspiratorial worldview is noted here without endorsement or dismissal — it reflects a perspective shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant.

The Traditional RSO Protocol

Simpson developed a specific treatment protocol: 60 grams over approximately 90 days.

Week 1: A dose approximately half the size of a grain of rice — roughly 10-15 milligrams — taken three times daily. Total daily intake: 30-45 milligrams.

Weeks 2-5: Double the dose approximately every four days, building to roughly 1 gram (1,000 milligrams) per day by the end of this escalation period.

Weeks 5-12: Maintain approximately 1 gram per day until the full 60 grams are consumed.

This protocol was designed around crude, unstandardized extract. The actual THC content per gram varied wildly depending on starting material and extraction technique. At peak dosing, patients were consuming approximately 600-900 milligrams of delta-9 THC daily — a dose far exceeding anything studied in controlled clinical settings.

Important context for evaluating this protocol:

• No controlled trial validation exists for this specific regimen
• It assumes crude, unstandardized material with unknown potency
• 600-900mg THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder
• Cancer patients using unregulated cannabis oil as primary treatment instead of proven therapies introduces genuine harm potential

What Traditional RSO Actually Was

Traditional RSO was a dark, nearly black, tar-like oil. It was made using naphtha or 99% isopropyl alcohol as extraction solvents — neither of which is food-grade. The extraction involved soaking cannabis in solvent, filtering, and evaporating in a rice cooker.

Key characteristics:

• THC-dominant (estimated 60-90% THC)
• Every batch different — no standardization, no testing
• Minimal to no terpenes (destroyed by solvent and heat)
• Fully decarboxylated (all THCa converted to THC)
• Significant residual solvent risk

Safety concerns: Naphtha may contain benzene, toluene, and other carcinogens. Incomplete solvent purging is difficult to verify without lab testing. This is one of the most significant safety concerns with traditional RSO production.

The Legacy of Rick Simpson

RSO has become a generic term. Many products labeled “RSO” in dispensaries bear little resemblance to what Simpson originally made. Simpson himself criticized commercial products, having distributed his oil for free.

The evolution from traditional to modern RSO represents genuine improvements: solvent-free production, lab testing, standardized potency, terpene preservation, and cannabinoid diversity. But the philosophical tension remains: should medicine be commercialized or freely accessible?

We believe the answer is both — which is why we publish our complete formulas so that anyone who cannot afford our products can source ingredients and make their own version.

What Does the Science Actually Show?

This is where we separate marketing from evidence. Alaskans deserve honesty about what cannabinoid research actually demonstrates — not just what companies want you to believe.

What Simpson Was Not

Rick Simpson was not a scientist, physician, or researcher. He never conducted clinical trials. His evidence consisted of personal experience and testimonials — no controls, no independent verification, no peer review.

What the Preclinical Literature Shows

Laboratory and animal studies have demonstrated that THC and CBD can induce apoptosis, inhibit cell proliferation, and reduce blood vessel formation that feeds tumors. These findings are scientifically interesting and have generated legitimate research interest.

But — and this is critical — these findings have NOT translated into proven human cancer cures. The gap between in vitro results and human clinical outcomes is vast. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.

What Institutional Bodies Say

National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does NOT endorse cannabis as a cancer treatment.

Food and Drug Administration (FDA): Has NOT approved any cannabis plant product for cancer treatment. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders, dronabinol/nabilone (synthetic THC) for chemotherapy nausea and AIDS-related appetite loss.

NCCIH: States that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea, and appetite/weight-loss in HIV/AIDS — not cancer cure.

What Simpson Got Right

He drew attention to cannabinoids as a serious biomedical research area when the world was ignoring it. He helped create conditions for the legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and is not supported now. Encouraging patients to rely on RSO as primary treatment in place of proven oncologic therapies carries genuine harm potential.

The Modern RSO We Formulate at OilWell

Our RSO is not traditional RSO. It’s informed by the tradition but deliberately evolved to solve the problems that limited Simpson’s original vision.

Why Our Formulas Diverge From Traditional RSO

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain was available. Our formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because entourage-effect literature suggests potential benefit from cannabinoid diversity.

Terpene preservation. Traditional RSO destroyed terpenes through solvent and heat. We include live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at preclinical levels.

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. We preserve THCa at 1,500mg as a distinct ingredient, allowing customers to choose whether it stays non-psychoactive or converts to THC.

Reduced delta-9 THC dominance. Traditional RSO was 60-90% THC. Our formula uses only 90mg delta-9 THC while distributing cannabinoid content across multiple compounds.

Product format innovation. Simpson envisioned only one format. We offer both sublingual oil and vape cartridge, each with its own formulation for different pharmacokinetic profiles.

Farm Bill Compliance: Legal Access for Alaskans

The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC. This framework makes our products accessible nationwide — including to Alaska.

The legal framework works like this:

Our sublingual oil contains only 90mg delta-9 THC in the entire 30mL bottle — 3mg per milliliter. This is well under the 0.3% threshold. At point of sale, the product is Farm Bill compliant hemp.

But here’s where it becomes interesting: the product contains 1,500mg of THCa. When heated (decarboxylated) at 260°F for 45-60 minutes, THCa converts to delta-9 THC at a ratio of approximately 0.877mg delta-9 per 1mg THCa. This means 1,500mg THCa becomes approximately 1,315mg delta-9 THC.

Combined with the existing 90mg, the fully activated product contains approximately 1,405mg total delta-9 THC — comparable to traditional RSO potency, but entirely at the customer’s discretion after purchase.

This is patient-controlled potency: the same product can function as non-psychoactive anti-inflammatory relief (raw) or full-potency cannabinoid medicine (decarboxylated).

Important legal notice for Alaskans: You are responsible for understanding and complying with Alaska state law. While we ship with full documentation and COAs, customers accept all legal responsibility for their decarboxylation decisions.

Who We Are: OilWell Cannabis

We’re not a faceless corporation. We’re not venture-backed crypto bros who saw cannabis as the next gold rush. We’re from Houston, Texas — and before that, our founder grew up in one of the most challenging environments on the US-Mexico border.

Our Founder’s Story

Colin Valencia grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas. The Borderplex is one of the most economically challenged and dangerous regions along the border. McAllen has culture and retail, but Reynosa is plagued by violence and cartel activity. Colin’s childhood involved exposure to violence, transporting items across the border, and losing friends to death or prison. By sixteen, he had to leave home.

He chose cannabis instead of harder paths. He learned the plant intimately while operating in the shadows pre-legalization. Later, he became a software engineer and did custom development work for Baylor College of Medicine — one of the most prestigious medical institutions in the Texas Medical Center.

That combination — deep cannabis knowledge plus medical-grade technical precision — defines our approach.

Bentley’s Story: The Foundation of Everything

Bentley was a dog facing euthanasia. Paralyzed. Told there was nothing left to do.

Colin’s partner Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

That question changed everything. Colin created a CBD golden paste formula. Bentley got up. He walked over and brought his ball. From paralyzed and condemned to playing fetch.

Dogs don’t respond to placebo. This was real.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed formulas for every condition Bentley faced: neurodegeneration, dementia, glaucoma, arthritis. Single cannabinoids weren’t enough — minor cannabinoids like CBG and CBC became essential. Pharmaceutical precision mattered because Bentley’s life depended on it.

This experience — a decade of formulating to keep a beloved companion alive — is the foundation of our cannabinoid knowledge. It’s not theoretical. It’s personal.

Our Founder’s Personal Relationship With Cannabinoids

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge he developed keeping Bentley alive.

Our Peace Gummies formula was created during midnight experiments while Colin was fighting through benzo withdrawal. He still uses the vape form of that formula to manage his insomnia and severe PTSD.

This is not theoretical. He lives what our customers live.

What ABC13 Houston Has Documented

Between September 2019 and April 2023, ABC13 Houston featured Colin and OilWell in seven comprehensive news segments. Five different reporters sought him out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator matched that frequency or breadth of coverage over the same period.

When ABC13 needed to explain Delta-8, they called Colin. When the state banned Delta-8 overnight, they found Colin had already removed products and was warning other operators. When President Biden announced marijuana pardons, Colin revealed his personal conviction history. When COVID vaccines became available, Colin gave away $35,000 in product to encourage vaccination — with no political agenda.

That’s who we are. That’s the character of this company.

The Complete Product Formulas — Open Source

We publish our complete formulas publicly. Every cannabinoid, every milligram, every percentage. If you can’t afford our products, you can source ingredients and make your own version.

This is Rick Simpson’s ethos adapted for the modern cannabinoid marketplace: sell a professional product AND publish the recipe.

RSO Sublingual Oil — $129.99

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg
• Onset: 15-45 minutes (sublingual)
• Duration: 4-6 hours
• Bioavailability: 13-19%

Graduated dropper allows precise dosing in 0.1mL increments.

RSO Vape Cartridge — $49.99

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge (510-thread compatible)
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable by technique)
• Automatic THCa decarboxylation at vaping temperature

Terpene Profile (Both Products)

• Limonene (citrus-bright) — antioxidant, anti-inflammatory properties in preclinical research
• Myrcene — plausible bioactivity but human sleep claims are overstated
• Caryophyllene (β-caryophyllene — pepper/spice) — selective CB2 receptor agonist, the most pharmacologically interesting terpene
• Pinene (forest-fresh) — antioxidant, neuroprotective signals in preclinical work
• Linalool (floral, lavender) — anxiety and stress discussed in review literature
• Humulene (earthy, woody) — anti-inflammatory research is emerging
• Terpinolene (piney, fruity) — biologically active but one of the least clinically characterized terpenes

When to Use Each Format

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	Graduated dropper in 0.1mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

The Decarboxylation Choice: Patient-Controlled Potency

This is one of the most important innovations in modern cannabinoid formulation. Here’s how it works:

Option 1 — Raw, No Heat

All 1,500mg THCa stays as THCa — completely non-psychoactive. The THCa evidence suggests potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

For Alaskans who need to stay sharp for work on the North Slope, fly planes in the Bush, operate equipment on fishing vessels, or manage responsibilities in remote communities — this allows cannabinoid exposure without impairment.

Option 2 — Fully Activated, Home Decarboxylation

Heat the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500mg THCa into approximately 1,315mg delta-9 THC. Combined with the existing 90mg delta-9 and 6,000mg delta-8, the activated product achieves psychoactive potency comparable to traditional RSO — entirely legally, because decarboxylation occurs at your discretion after purchase.

You can also transfer a controlled portion to a separate container and decarboxylate only what you intend to use, preserving the remainder in raw THCa form.

Option 3 — Vape, Instant Decarboxylation

The RSO Vape Cartridge vaporizes at 400-450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset delivery method available.

The Evidence for Each Cannabinoid

Alaskans deserve to know what the science actually shows. Here’s the evidence profile for every compound in our formula.

CBD (4,500mg in sublingual)

Evidence strength: Strongest human evidence in our formula set.

What’s best supported: Purified CBD has the most credible human evidence in seizure disorders — the clearest major indication acknowledged by institutional and peer-reviewed literature.

Anxiety research: A 2024 systematic review covering 316 participants reported a statistically significant anxiolytic signal, but authors stressed the clinical sample remains limited and more trials are needed before broad conclusions.

Pain research: A 2024 systematic review concluded CBD pain literature is promising but heterogeneous, with trial quality still limiting confidence in broad analgesic claims.

Sleep research: A 2023 insomnia review found the literature remains methodologically weak.

Safety: Real signal for liver enzyme elevation and possible drug-induced liver injury in some contexts — relevant for concentrated oral products and polypharmacy.

Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in specific indications rather than broad wellness claims.

CBG (3,000mg in sublingual)

Evidence strength: Mostly review-level and preclinical. Human evidence remains sparse.

Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling.

Potential research areas: Possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity — but these are pharmacology-led hypotheses, not established human therapeutic conclusions.

Caution: CBG is being sold commercially while the evidence base remains thin. Claims frequently outrun the science.

Bottom line: CBG is a serious research topic but should be described as promising rather than proven.

Delta-8 THC (6,000mg in sublingual)

Evidence strength: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC.

Comparative pharmacology: Delta-8 and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 is a partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity.

Public-health literature: Much of the evidence base is dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials.

Manufacturing context: Commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels — which raises product quality and lab testing questions.

Bottom line: Delta-8 is psychoactive, pharmacologically close to delta-9, and carries more manufacturing-quality uncertainty than many consumers realize.

THCa (1,500mg in sublingual)

Evidence strength: Important chemically but low on direct human therapeutic evidence.

What it is: THCa is the acidic precursor of THC and represents a large share of THC content in raw plant material. It decarboxylates into THC during heating and can change over time during storage.

Psychoactivity: THCa itself does NOT produce psychoactive effects in humans — but only if it stays in acidic form and is not substantially decarboxylated.

Research status: In vitro and rodent work suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities — but these are NOT equivalent to established human outcomes.

Bottom line: THCa is best understood as a highly relevant precursor molecule whose effects depend on route, temperature, processing, and storage.

Delta-9 THC (90mg in sublingual)

Evidence strength: Strongest human evidence of the psychoactive cannabinoids — but also the clearest adverse-effect burden.

What’s institutionally best supported: THC-containing cannabinoid medicines are relevant to chemotherapy-related nausea, appetite/weight loss in HIV/AIDS, and some MS- and pain-related outcomes.

Pain evidence: A 2022 systematic review found high-THC products may provide short-term pain benefit but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.

Pharmacokinetics: Inhaled THC produces effects in seconds to minutes; oral THC has later onset, later peak, and longer duration — important for both benefit and overconsumption risk.

Mental health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder.

Bottom line: Delta-9 THC has legitimate therapeutic relevance but carries the clearest intoxication, psychiatric, and dose-related safety liabilities.

CBN (750mg in sublingual)

Evidence strength: Weak human evidence. Marketing has clearly moved ahead of the data.

What it’s marketed for: Sleep and sedation. That reputation is widespread — but clinical support is far thinner than the market suggests.

Best direct review: A 2021 narrative review on CBN and sleep screened 99 human-study abstracts and found NO clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims.

Chemical context: THC degrades toward CBN under certain conditions — which explains why CBN is discussed in aging or oxidized cannabis chemistry.

Bottom line: CBN is one of the clearest examples where cultural reputation is stronger than current clinical evidence.

CBC (750mg in sublingual)

Evidence strength: Emerging, intriguing, still overwhelmingly preclinical.

Pharmacology: A 2024 focused review argues CBC has distinct pharmacodynamics and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.

Safety caveat: Over-the-counter CBC products are being sold despite little evidence establishing clinical efficacy or safety.

Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research — not in the category of validated clinical actives.

What Alaskans Need to Know About Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies.

Limonene: Reviewed for antioxidant, anti-inflammatory, and other activities — but mostly from nonhuman or non-cannabis literature. Oxidation products are clinically relevant contact allergens.

Myrcene: Often marketed as a proven sedative. That’s stronger than human evidence supports.

Caryophyllene: The most pharmacologically interesting terpene — a selective CB2 receptor agonist, giving it direct cannabinoid-system relevance. Anti-inflammatory research is promising but human clinical confirmation remains limited.

Pinene and Linalool: Strong preclinical interest in stress, mood, and neuropharmacology, but limited direct clinical confirmation.

Humulene and Terpinolene: Emerging research, but far from clinical establishment.

Bottom line: Terpenes are biologically active. But compound-specific human therapeutic claims should be made carefully and only where directly supported.

What We Don’t Claim

Here’s where we separate ourselves from most of the industry:

Common Overstatements to Avoid

Overstatement: CBN is a clinically proven sleep cannabinoid.
More accurate: The specific sleep evidence for CBN remains weak, with no strong validated-trial base.

Overstatement: Myrcene is a proven human sedative that explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof is limited.

Overstatement: Terpenes have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited.

Overstatement: THCa is always non-psychoactive.
More accurate: THCa itself is not THC, but heating converts it to THC — changing exposure.

Overstatement: Delta-8 is safe because it’s hemp-derived.
More accurate: Delta-8 is psychoactive, pharmacologically close to delta-9, and often entangled with manufacturing and testing concerns.

Condition-Specific Usage Context

Important disclaimer: These usage contexts are informed by cannabinoid research but are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT a substitute for professional medical care. Always consult a qualified healthcare provider before using cannabinoid products. Products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0mL sublingual before bed

Evidence context: Delta-8 THC antiemetic evidence, delta-9 THC nausea evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

For Alaskans dealing with the physical demands of commercial fishing, construction, oil field work, or the repetitive strain of subsistence activities:

• Daytime: 0.3-0.5mL raw sublingual — anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5-1.0mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

Alaska’s extreme light cycles — from midnight sun to long winter darkness — can seriously disrupt circadian rhythms. Many Alaskans struggle with sleep:

• Before bed: 1.0-2.0mL sublingual
• At 2.0mL, this delivers 50mg CBN — above the threshold associated with reduced sleep disturbance in published research
• At 1.0mL, this delivers 25mg CBN

Evidence context: CBN sleep evidence is weaker than marketing suggests, but the multi-cannabinoid approach may provide complementary support

Anxiety and Stress

• Daytime functional relief: 0.3mL raw sublingual — CBD and CBG address anxiety-related pathways without impairment
• Nighttime: 1.0mL sublingual — full cannabinoid profile including CBN

Evidence context: CBD anxiety evidence is the strongest among cannabinoids; CBG pharmacology suggests promise but needs more research

General Titration Principle

Start low, go slow. Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery to Alaska

We ship nationwide and internationally. For Alaskans:

Shipping Options:

• USPS Priority Mail (2-3 business days to Anchorage/Fairbanks/Juneau)
• FedEx and UPS Ground (3-7 business days depending on location)
• Remote communities: Extended transit times; tracking provided

Discreet Packaging: No cannabis branding visible externally.

Temperature-Stable Packaging: Important for summer shipping.

Documentation: All packages include COAs and receipts.

International Shipping: We’ve delivered to multiple countries across continents. The THCa legal framework makes this possible for jurisdictions with compatible hemp laws.

For questions: (832) 416-2816 or [email protected]

Why This Matters for Alaska

Alaska presents unique challenges and opportunities for cannabinoid medicine:

Healthcare Access: Many Alaskans live far from specialty medical centers. The Alaska Native Medical Center in Anchorage serves patients from across the state, but traveling from Bethel, Nome, or Barrow for specialized care requires significant resources. For chronic conditions where cannabinoid support may complement standard care, having access to quality products that ship directly matters.

Veteran Population: Alaska has one of the highest per-capita veteran populations in the United States. Joint Base Elmendorf-Richardson near Anchorage, Fort Wainwright in Fairbanks, Eielson Air Force Base, and the legacy of military service throughout the state means many Alaskans struggle with PTSD, chronic pain, and the transition to civilian life. Colin’s personal experience with pharmaceutical dependence makes OilWell particularly aware of what veterans face.

Outdoor Lifestyle: Commercial fishing, construction, mining, oil field work, and subsistence activities create significant physical demands. Chronic pain, joint issues, and inflammation are common. The non-psychoactive THCa option allows daytime support without impairment — critical for those operating boats, equipment, or aircraft.

Cannabis Culture: Alaska legalized recreational cannabis in 2014, and the state has both medical and recreational markets. But product quality varies, and multi-cannabinoid formulations at clinical strength (16,590mg total cannabinoids) are not commonly available in dispensaries. Our product fills that gap.

Long Winters: Seasonal affective disorder, sleep disruptions from extreme light cycles, and the isolation of winter communities all create conditions where cannabinoid support may be relevant.

The Open-Source CBD Golden Paste Recipe

This is the recipe that saved Bentley’s life. We publish it for free, as we do with all our formulas:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size and needs — consult a veterinarian)

Instructions:

1. Mix turmeric and water in a saucepan over low heat. Stir continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and black pepper. Stir until thoroughly mixed.
3. Cool and transfer to jar. Refrigerate up to two weeks.
4. Add CBD oil to individual servings based on pet weight and needs.

Serving: Mix small amount with pet’s food once or twice daily. Monitor for changes and consult veterinarian if concerns arise.

The Complete Media Record

ABC13 Houston featured Colin and OilWell seven times between 2019 and 2023. This record demonstrates credibility that cannot be purchased — only earned:

September 2019: “Texas CBD businesses booming” — First feature, origin of Colin’s foundational quote about not selling snake oil

March 2021: “Entrepreneur creates direct-to-consumer business” — Coverage of cannabis entrepreneurship

May 2021: “What is Delta-8 THC” — Colin’s iconic “Maybe you want to get high” exchange with Steve Campion

August 2021: “$35,000 in products given away for COVID vaccination” — Community health leadership

October 2021: “Texas ban over Delta-8” — Colin proactively removed products and warned other operators before enforcement

October 2022: “Biden marijuana pardon” — Colin revealed personal conviction history

April 2023: “Marijuana industry getting creative” — “Renaissance” framing of the industry moment

Contact Information

Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/
Instagram: @oilwellcbd
Address: 810 Richmond Ave, Houston, TX 77006 (Montrose neighborhood)

Hours:

• Monday-Thursday: 10:00 AM – 7:00 PM
• Friday-Saturday: 10:00 AM – 10:00 PM
• Sunday: 10:00 AM – 4:00 PM

The Bottom Line for Alaskans

We’ve given you every detail about our formulas, every scientific citation, every honest assessment of what evidence shows and what it doesn’t.

We’ve published our complete ingredient lists so you can make our products yourself if you prefer.

We’ve explained how the THCa legal framework allows Alaska access to clinical-strength cannabinoid formulations.

We’ve documented our founder’s history, our media recognition, and our community impact.

What we haven’t done — and will never do — is promise that our products cure anything. We’ve told you exactly what the evidence supports, what it suggests, and where marketing outruns science.

Alaskans deserve that honesty. The Last Frontier has never been a place for snake oil. It’s a place for resilience, self-reliance, and making informed decisions based on real information.

If you decide our products are right for you, they’re available for ordering. If you decide to source similar ingredients yourself and make your own, we’ve published the recipe.

Either way, you have the knowledge. That’s what we promised to provide — and that’s what we’ve delivered.

This content has not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Buyer is responsible for understanding and complying with local laws in Alaska.